Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Research & Development (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Research & Development for 13 consecutive years, with $8.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development changed N/A to $8.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $39.5 million, a N/A change, with the full-year FY2024 number at $37.6 million, down 7.33% from a year prior.
  • Research & Development was $8.1 million for Q3 2025 at Theravance Biopharma, down from $10.5 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $67.6 million in Q1 2021 to a low of -$99.0 million in Q4 2022.
  • A 5-year average of $12.8 million and a median of $10.5 million in 2025 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: plummeted 77.44% in 2022, then grew 27.7% in 2025.
  • Theravance Biopharma's Research & Development stood at $43.7 million in 2021, then crashed by 326.43% to -$99.0 million in 2022, then soared by 108.39% to $8.3 million in 2023, then rose by 13.74% to $9.5 million in 2024, then dropped by 14.19% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for TBPH's Research & Development are $8.1 million (Q3 2025), $10.5 million (Q2 2025), and $11.5 million (Q1 2025).